Valuation: Aradigm Corporation

Market Cap 48.85L 41.87L 39.17L 35.81L 67.57L 47Cr 68.29L 4.63Cr 1.8Cr 23Cr 1.83Cr 1.79Cr 78Cr P/E 2016
-0.72x
P/E 2017 -9.3x
Enterprise Value 1.28Cr 1.1Cr 1.03Cr 93.81L 1.77Cr 122.55Cr 1.79Cr 12Cr 4.72Cr 62Cr 4.81Cr 4.7Cr 203.6Cr EV / Sales 2016
73.3x
EV / Sales 2017 7.27x
Free-Float
60.28%
Yield 2016 *
-
Yield 2017 -
Change 5-day change 1-year change 3-year change Capi.($)
+36.88%+25.50% - - 7L
-0.74%+3.78%+3.74%+23.10% 5.16TCr
+1.01%-0.20%+471.68%+564.93% 4.49TCr
+0.16%+7.88%+36.14%+20.76% 4.28TCr
-0.66%+2.61%+18.59%+87.04% 4.26TCr
+0.88%-3.48%+17.20%+57.20% 3.18TCr
-0.12%+3.84%+33.73%+145.25% 1.73TCr
-0.53%+1.84% - - 1.66TCr
+0.58%+4.66%+7.17%+30.87% 1.48TCr
+1.15%+4.17%+84.49%+50.33% 1.41TCr
Average +3.86%+4.62%+84.09%+122.43% 3.07TCr
Weighted average by Cap. +0.10%+4.83%+100.58%+141.04%

Financials

2016 2017
Net sales 2L 2L 2L 1L 3L 1.87Cr 3L 18.5L 7L 93.76L 7L 7L 3.1Cr 1.45Cr 1.24Cr 1.16Cr 1.06Cr 2Cr 138.51Cr 2.02Cr 14Cr 5.34Cr 70Cr 5.43Cr 5.31Cr 230.11Cr
Net income -3.29Cr -2.82Cr -2.64Cr -2.41Cr -4.56Cr -315.39Cr -4.6Cr -31Cr -12Cr -158.37Cr -12Cr -12Cr -523.99Cr -1.07Cr -91.74L -85.83L -78.47L -1.48Cr -102.5Cr -1.5Cr -10Cr -3.95Cr -51Cr -4.02Cr -3.93Cr -170.3Cr
Net Debt -93.72L -80.32L -75.14L -68.69L -1.3Cr -90Cr -1.31Cr -8.89Cr -3.46Cr -45Cr -3.52Cr -3.44Cr -149.09Cr 79.13L 67.81L 63.44L 58L 1.09Cr 76Cr 1.11Cr 7.51Cr 2.92Cr 38Cr 2.97Cr 2.91Cr 125.88Cr
Logo Aradigm Corporation
Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.
Employees
-